vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的36.4倍（$281.3M vs $7.7M）。AMERICAN SHARED HOSPITAL SERVICES净利率更高（-8.2% vs -45.7%，领先37.5%）。Guardant Health, Inc.同比增速更快（39.4% vs -14.8%）。AMERICAN SHARED HOSPITAL SERVICES自由现金流更多（$-2.7M vs $-54.2M）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 21.7%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
AMS vs GH — 直观对比
营收规模更大
GH
是对方的36.4倍
$7.7M
营收增速更快
GH
高出54.2%
-14.8%
净利率更高
AMS
高出37.5%
-45.7%
自由现金流更多
AMS
多$51.5M
$-54.2M
两年增速更快
GH
近两年复合增速
21.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $281.3M |
| 净利润 | $-631.0K | $-128.5M |
| 毛利率 | 11.7% | 64.6% |
| 营业利润率 | -18.1% | -43.0% |
| 净利率 | -8.2% | -45.7% |
| 营收同比 | -14.8% | 39.4% |
| 净利润同比 | 52.5% | -15.8% |
| 每股收益（稀释后） | $-0.09 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSGH
| Q4 25 | $7.7M | $281.3M | ||
| Q3 25 | $7.2M | $265.2M | ||
| Q2 25 | $7.1M | $232.1M | ||
| Q1 25 | $6.1M | $203.5M | ||
| Q4 24 | $9.1M | $201.8M | ||
| Q3 24 | $7.0M | $191.5M | ||
| Q2 24 | $7.1M | $177.2M | ||
| Q1 24 | $5.2M | $168.5M |
净利润AMSGH
| Q4 25 | $-631.0K | $-128.5M | ||
| Q3 25 | $-17.0K | $-92.7M | ||
| Q2 25 | $-280.0K | $-99.9M | ||
| Q1 25 | $-625.0K | $-95.2M | ||
| Q4 24 | $-1.3M | $-111.0M | ||
| Q3 24 | $-207.0K | $-107.8M | ||
| Q2 24 | $3.6M | $-102.6M | ||
| Q1 24 | $119.0K | $-115.0M |
毛利率AMSGH
| Q4 25 | 11.7% | 64.6% | ||
| Q3 25 | 22.1% | 64.7% | ||
| Q2 25 | 23.1% | 65.0% | ||
| Q1 25 | 15.4% | 63.3% | ||
| Q4 24 | 35.3% | 61.6% | ||
| Q3 24 | 19.6% | 61.1% | ||
| Q2 24 | 35.0% | 59.1% | ||
| Q1 24 | 41.1% | 61.2% |
营业利润率AMSGH
| Q4 25 | -18.1% | -43.0% | ||
| Q3 25 | -4.8% | -37.3% | ||
| Q2 25 | -7.7% | -45.9% | ||
| Q1 25 | -21.3% | -54.6% | ||
| Q4 24 | -20.2% | -62.4% | ||
| Q3 24 | -12.7% | -61.3% | ||
| Q2 24 | -0.0% | -56.8% | ||
| Q1 24 | -1.6% | -59.2% |
净利率AMSGH
| Q4 25 | -8.2% | -45.7% | ||
| Q3 25 | -0.2% | -35.0% | ||
| Q2 25 | -4.0% | -43.0% | ||
| Q1 25 | -10.2% | -46.8% | ||
| Q4 24 | -14.6% | -55.0% | ||
| Q3 24 | -3.0% | -56.3% | ||
| Q2 24 | 51.0% | -57.9% | ||
| Q1 24 | 2.3% | -68.2% |
每股收益（稀释后）AMSGH
| Q4 25 | $-0.09 | $-1.01 | ||
| Q3 25 | $0.00 | $-0.74 | ||
| Q2 25 | $-0.04 | $-0.80 | ||
| Q1 25 | $-0.10 | $-0.77 | ||
| Q4 24 | $-0.21 | $-0.90 | ||
| Q3 24 | $-0.03 | $-0.88 | ||
| Q2 24 | $0.55 | $-0.84 | ||
| Q1 24 | $0.02 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $378.2M |
| 总债务越低越好 | $17.4M | $1.5B |
| 股东权益账面价值 | $24.0M | $-99.3M |
| 总资产 | $55.5M | $2.0B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSGH
| Q4 25 | $3.5M | $378.2M | ||
| Q3 25 | $5.1M | $580.0M | ||
| Q2 25 | $11.1M | $629.1M | ||
| Q1 25 | $11.2M | $698.6M | ||
| Q4 24 | $11.0M | $525.5M | ||
| Q3 24 | $13.8M | $585.0M | ||
| Q2 24 | $14.2M | $933.7M | ||
| Q1 24 | $12.8M | $1.0B |
总债务AMSGH
| Q4 25 | $17.4M | $1.5B | ||
| Q3 25 | $18.2M | $1.1B | ||
| Q2 25 | $19.1M | $1.1B | ||
| Q1 25 | $19.9M | $1.1B | ||
| Q4 24 | $20.4M | $1.1B | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.6M | — |
股东权益AMSGH
| Q4 25 | $24.0M | $-99.3M | ||
| Q3 25 | $24.6M | $-354.5M | ||
| Q2 25 | $24.5M | $-305.5M | ||
| Q1 25 | $24.6M | $-250.8M | ||
| Q4 24 | $25.2M | $-139.6M | ||
| Q3 24 | $26.4M | $-60.1M | ||
| Q2 24 | $26.5M | $-1.6M | ||
| Q1 24 | $22.8M | $68.3M |
总资产AMSGH
| Q4 25 | $55.5M | $2.0B | ||
| Q3 25 | $59.6M | $1.3B | ||
| Q2 25 | $63.5M | $1.3B | ||
| Q1 25 | $63.3M | $1.3B | ||
| Q4 24 | $60.2M | $1.5B | ||
| Q3 24 | $63.3M | $1.5B | ||
| Q2 24 | $60.8M | $1.6B | ||
| Q1 24 | $50.1M | $1.7B |
负债/权益比AMSGH
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $-54.2M |
| 自由现金流率自由现金流/营收 | -34.8% | -19.3% |
| 资本支出强度资本支出/营收 | 25.7% | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流AMSGH
| Q4 25 | $-704.0K | $-26.4M | ||
| Q3 25 | $1.7M | $-35.4M | ||
| Q2 25 | $-372.0K | $-60.3M | ||
| Q1 25 | $2.5M | $-62.7M | ||
| Q4 24 | $274.0K | $-64.5M | ||
| Q3 24 | $472.0K | $-51.1M | ||
| Q2 24 | $1.3M | $-94.0M | ||
| Q1 24 | $-1.9M | $-30.3M |
自由现金流AMSGH
| Q4 25 | $-2.7M | $-54.2M | ||
| Q3 25 | $-2.0M | $-45.8M | ||
| Q2 25 | $-2.3M | $-65.9M | ||
| Q1 25 | $-1.5M | $-67.1M | ||
| Q4 24 | $-4.4M | $-83.4M | ||
| Q3 24 | $-407.0K | $-55.3M | ||
| Q2 24 | $70.0K | $-99.1M | ||
| Q1 24 | $-3.0M | $-37.2M |
自由现金流率AMSGH
| Q4 25 | -34.8% | -19.3% | ||
| Q3 25 | -28.3% | -17.3% | ||
| Q2 25 | -32.1% | -28.4% | ||
| Q1 25 | -24.7% | -33.0% | ||
| Q4 24 | -48.4% | -41.3% | ||
| Q3 24 | -5.8% | -28.9% | ||
| Q2 24 | 1.0% | -55.9% | ||
| Q1 24 | -58.4% | -22.1% |
资本支出强度AMSGH
| Q4 25 | 25.7% | 9.9% | ||
| Q3 25 | 51.6% | 3.9% | ||
| Q2 25 | 26.9% | 2.4% | ||
| Q1 25 | 65.7% | 2.2% | ||
| Q4 24 | 51.4% | 9.4% | ||
| Q3 24 | 12.6% | 2.2% | ||
| Q2 24 | 17.2% | 2.9% | ||
| Q1 24 | 22.7% | 4.1% |
现金转化率AMSGH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
